Replies to post #508 on Javelin Pharmaceuticals Inc (JAV)

[Bio_pete]

Why don't you look at the positives instead of the negatives. Could you be one of those shorts? "Ketamine results are baked in" Your crazy, how can it be baked in when their talking about an accelerated review process.

"Cash burn rate increasing", thats not always a bad thing with biotechs, it means your clinical trials are advancing. They still have $47 million on the balance sheet so cash is not a concern next yr.

How about the positives, like they anticipate sales ramping up quickly for Dyloject in the UK & German markets. Clinical trials are progressing well.

[Nerf]

I don't disagree about the lengthening of the time frame, and the cash burn. As for the insitutions, and or the shorts, depends on the time frame. If the 35% are here for a year or more, then they're not going to bail because of the CC, the recent news, or any other reason, IMO. Unless there's something poor about the meeting next week and the following PR, then all bets are off. But as AFAICT, the story continues to play out, albeit slightly more slowly than I had had in mind. The three months to six months before actual sales kinda took me by surprise, as did the next country (Germany) having to wait until that stage was over before getting the approval process going.

Good thing, back of the envelope, IMO they won't need another deal/financing if sales of Dyloject ramp to max in 12 months like they projected.

[rsox]

done for months? did you conduct an interview of the shorts?
and more importantly since im trying to evaluate you for the bs factor are you short...i know you are shortimer here but did you go short this morning since you have no fear.

im trolling for wisdom....hook a brother up.